NovaBay Pharmaceuticals, Inc. (NBY) News
Filter NBY News Items
NBY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NBY News Highlights
- NBY's 30 day story count now stands at 2.
- Over the past 26 days, the trend for NBY's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest NBY News From Around the Web
Below are the latest news stories about NovaBay Pharmaceuticals Inc that investors may wish to consider to help them evaluate NBY as an investment opportunity.
NovaBay Pharmaceuticals Engages Leading Chinese Marketing Firm to Drive Consumer Sales of DERMAdoctor Skincare Products in ChinaEMERYVILLE, Calif., February 23, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces the engagement of one of China’s leading marketing firms for omnichannel integrated marketing and branding services of DERMAdoctor skincare products in China. NovaBay’s new marketing partner will also manage DERMAdoctor’s online flagship store on Tmall.com, the leading business-to-cons |
NovaBay Pharmaceuticals Announces Changes to Its Board of DirectorsEMERYVILLE, Calif., January 28, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focused on developing and commercializing high-quality, scientifically formulated products for the eyecare and skincare markets, announces the appointments of Audrey Kunin, M.D. and Julie Garlikov to the NovaBay Board of Directors. Dr. Kunin is a recognized leader in the skincare product industry and has served as NovaBay’s Chief Product Officer since its acquisition in November 20 |
NovaBay Pharmaceuticals to Donate 2.5 Million KN95 MasksEMERYVILLE, Calif., January 20, 2022--NovaBay Pharmaceuticals donates 2.5 million KN95 protective masks. |
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of StockholdersEMERYVILLE, Calif., January 20, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company"), a pharmaceutical company focused on developing and commercializing high-quality, scientifically formulated products for the eyecare and skincare markets, announces that its Special Meeting of Stockholders held on December 17, 2021, as adjourned to and reconvened on January 14, 2022, has been further adjourned until January 31, 2022 at 11:00 a.m. Pacific time in order to provide |
NovaBay Pharmaceuticals Expands Its Eyecare Product Portfolio With the Launch of Lubricating Eye Drops for the Immediate Relief of Dry Eye SymptomsEMERYVILLE, Calif., January 10, 2022--NovaBay Pharmaceuticals launches Avenova Lubricating Eye Drops for the immediate relief of dry eye symptoms. |
NovaBay Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual ConferenceEMERYVILLE, Calif., January 04, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focused on developing and commercializing scientifically formulated and clinically proven consumer products for the eyecare and skincare markets, announces that management will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. A webcast of the NovaBay presentation will be available on the Events page of the company websi |
NovaBay Pharmaceuticals Holds Special Meeting of StockholdersEMERYVILLE, Calif., December 21, 2021--NovaBay Pharmaceuticals adjourns it Special Meeting of Stockholders until January 14, 2022 |
DERMAdoctor’s Calm Cool + Corrected Eczema Balm Receives National Eczema Association Seal of AcceptanceEMERYVILLE, Calif., December 13, 2021--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focused on developing and commercializing high-quality, scientifically formulated products for the eyecare and skincare markets, announces that DERMAdoctor’s Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm has received the National Eczema Association (NEA) Seal of Acceptance™. The NEA Seal is granted in recognition of products that meet the NEA’ |
Insider Buying: NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) CEO Acquires 69,767 Shares of StockNovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) CEO Justin Hall acquired 69,767 shares of NovaBay Pharmaceuticals stock in a transaction that occurred on Monday, December 6th. The shares were purchased at an average cost of $0.43 per share, with a total value of $29,999.81. The transaction was disclosed in a legal filing with the SEC, which is available [] |
Jeffrey Kunin Purchases 30,000 Shares of NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) StockNovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) insider Jeffrey Kunin bought 30,000 shares of the firms stock in a transaction dated Tuesday, November 30th. The shares were acquired at an average cost of $0.46 per share, with a total value of $13,800.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is [] |